Acticor Biotech (XPAR:ALACT) Long-Term Capital Lease Obligation : €0.00 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Long-Term Capital Lease Obligation?

Acticor Biotech's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil.

Acticor Biotech's annual Long-Term Capital Lease Obligation declined from Dec. 2020 (€0.05 Mil) to Dec. 2021 (€0.00 Mil) but then stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil).

Acticor Biotech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Acticor Biotech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Long-Term Capital Lease Obligation Chart

Acticor Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.17

0.11

0.05

Acticor Biotech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial				0.02	-	-	-	-

Acticor Biotech (XPAR:ALACT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Acticor Biotech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Acticor Biotech (XPAR:ALACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

7V7:Germany

Address

82 Avenue du Maine, Wojo Building, Paris, FRA, 75014

Website

https://www.acticor-biotech.com

Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines